EVEREST-1: A Seamless Phase 1/2 Study to Evaluate the Safety and Efficacy of A2B530 an Autologous Logic-gated Tmod CAR T in Heterozygous HLA-A*02 Adults with Recurrent Unresectable Locally Advanced or Metastatic Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression

Brief description of study

This is a first-in-human, seamless Phase 1/2, multicenter, open-label, nonrandomized study. This study consists of Phase 1 dose-escalation and dose-expansion portions and a Phase 2 cohort-expansion portion.The primary objectives of Phase 1 are to evaluate the safety and tolerability of A2B530, and to determine the recommended Phase 2 dose (RP2D).The primary objective of Phase 2 is to evaluate the efficacy of A2B530.


Clinical Study Identifier: s23-00280
ClinicalTrials.gov Identifier: NCT05736731


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.